Physician profile
Andrea Rodriguez Kawas
NPI 1780107235
$1,255.80
in general payments reported to CMS, 2019-2025
21 companies · $208 in 2025
The $208 reported for 2025 was more than what 83% of Hospice and Palliative Medicine (Anesthesiology) providers received nationally (typical 2025 total: $65.12).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $323 · 2023: $304 · 2024: $420 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $932.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $312.32 | 2022-2023 | Repatha |
| Abbvie INC. | $231.94 | 2022-2025 | Linzess |
| Lilly USA, LLC | $194.85 | 2022-2025 | Mounjaro, Zepbound, Emgality |
| Shield Therapeutics INC | $67.63 | 2024 | |
| Novo Nordisk INC | $66.13 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $52.73 | 2024-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.76 | 2022-2023 | Stiolto Respimat |
| Grifols USA, LLC | $25.19 | 2024 | Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $25.00 | 2023 | Nucala |
| Genzyme Corporation | $23.92 | 2025 | |
| Viatris Specialty LLC | $22.48 | 2025 | Yupelri |
| Baxter Healthcare | $22.43 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Mylan Specialty L.P. | $21.94 | 2022 | |
| Astellas Pharma US INC | $21.69 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $20.13 | 2023 | Verquvo, Belsomra, Steglatro |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $19.84 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $19.50 | 2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $19.22 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.84 | 2025 | Caplyta |
| Scilex Pharmaceuticals INC. | $15.15 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Rodriguez Kawas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.